Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 6/20 | 0.80 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28583845 | 0.90 | NHERF1 (0.68) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL398391 | 0.89 | CFTR (1.00) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL29753973 | 0.88 | CFTR (0.63) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL20567521 | 0.88 | STING1 (0.64) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL6037542 | 0.88 | NPC1 (0.75) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL20567856 | 0.88 | CFTR (0.63) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL20567516 | 0.88 | STING1 (0.64) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL20567704 | 0.88 | STING1 (0.64) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL3767352 | 0.88 | CFTR (0.63) | CFTRNPC1MEN1KMT2ARAB9A | |
| SCHEMBL6037539 | 0.88 | CFTR (0.63) | CFTRNPC1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189278-A1 | NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION | KLOTHO THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024109642-A1 | USE OF BENZOAZACYCLIC COMPOUND AS ALLOSTERIC MODULATOR OF β2-ADRENOCEPTOR | 常州大学 | 2024-05-30 | — | — | WO | disclosed |
| CN-117447381-A | Indole amide derivative and its application in preparing beta 2 Use of adrenoreceptor allosteric antagonist medicaments | 常州大学 | 2024-01-26 | — | — | CN | disclosed |
| EP-3541817-B1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20180338951-A1 | TREATMENTS FOR ARTERIAL STIFFENING, HYPERTENSION AND ANTI-AGING | KLOTHO THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| WO-2018093968-A1 | IMIDAZOPYRIDAZINE MODULATORS OF IL-12, IL-23 AND/OR IFN-ALPHA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-3027602-A1 | NOVEL DERIVATIVES OF INDOLE AND PYRROLE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Les Laboratoires Servier (FR) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015011396-A1 | NOVEL DERIVATIVES OF INDOLE AND PYRROLE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2015-01-29 | — | — | WO | disclosed |
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2125718-A2 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-5464861-A | Anticarcinogenic agents | WARNER-LAMBERT (US) | 1995-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189278-A1 | NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION | COL2A1, COL1A1, COL14A1 | CFTR 3096/4885NPC1 3649/4885MEN1 1555/4885 |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | CFTR 4684/4885NPC1 1474/4885MEN1 4766/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CFTR 897/4885NPC1 799/4885MEN1 2039/4885 |
| US-20180338951-A1 | TREATMENTS FOR ARTERIAL STIFFENING, HYPERTENSION AND ANTI-AGING | COL2A1, COL1A1, COL14A1 | CFTR 3146/4885NPC1 4496/4885MEN1 519/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | CFTR 3215/4885NPC1 1723/4885MEN1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.